Gilead to Acquire Tubulis to Expand Oncology ADC Platform

Gilead Sciences has announced it will acquire Tubulis to strengthen its oncology pipeline science and therapeutic capabilities. The acquisition is described as adding TUB-040, a NaPi2b-targeting antibody drug conjugate (ADC) for ovarian cancer and other solid tumors, to Gilead’s pipeline.

The deal also includes Tubutecan linker-payload technology and a next-generation platform intended to expand Gilead’s ADC capabilities. The excerpt indicates the announcement was made by Gilead and Tubulis jointly from FOSTER CITY, Calif. and MUNICH.